Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc

In a report released on January 5, Geoff Meacham from Citi reiterated a Buy rating on Royalty Pharma, with a price target of $48.00. According to T...

Market Cap	$16.52B	P/E Ratio	9.15
52W High	$41.72	52W Low	$29.66
Div Yield	94.0%	Payout Ratio	427.0%
EPS Growth 3Y	8.8%	52W Position	105.3%
Overall Score	70	Value Score	100
Quality Score	52	Technical Score	60

EPS Current Est	$4.63	EPS Next Est	$5.09
EPS Growth Est	+9.9%	DPS Growth 3Y	7.3%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RPRX	$42.36	+1.63%	3.86M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RPRX	$42.36	+1.6%	3.86M
3
4
5
6

RPRX

RPRX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Royalty Pharma plc Data in Excel

Get Royalty Pharma plc Data in Excel